Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder

NCT01677182 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
535
Enrollment
INDUSTRY
Sponsor class

Stopped Business Decision; Terminated due to futility, with no safety concerns (see below)

Conditions

Interventions

Sponsor

Takeda